UnitedHealth Group (UNH) Given New $270.00 Price Target at Argus
UnitedHealth Group (NYSE:UNH) had its price target boosted by Argus to $270.00 in a research report sent to investors on Thursday. They currently have a buy rating on the healthcare conglomerate’s stock.
A number of other research firms also recently weighed in on UNH. Deutsche Bank boosted their target price on UnitedHealth Group to $260.00 and gave the stock a buy rating in a research report on Wednesday. Citigroup boosted their target price on UnitedHealth Group from $235.00 to $268.00 and gave the stock a buy rating in a research report on Wednesday. Piper Jaffray Companies restated a buy rating and set a $259.00 target price on shares of UnitedHealth Group in a research report on Wednesday. Royal Bank of Canada boosted their target price on UnitedHealth Group from $269.00 to $280.00 and gave the stock an outperform rating in a research report on Wednesday. Finally, BMO Capital Markets upped their price objective on UnitedHealth Group from $14.50 to $275.00 and gave the company an outperform rating in a report on Wednesday. Two research analysts have rated the stock with a hold rating and twenty-six have issued a buy rating to the company’s stock. The company has an average rating of Buy and an average price target of $243.22.
Shares of UnitedHealth Group (NYSE UNH) opened at $243.35 on Thursday. The firm has a market capitalization of $235,822.70, a price-to-earnings ratio of 24.14, a PEG ratio of 1.42 and a beta of 0.66. UnitedHealth Group has a 52-week low of $156.49 and a 52-week high of $244.35. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.70 and a current ratio of 0.73.
In other UnitedHealth Group news, Director Kenneth Irwin Shine sold 457 shares of the stock in a transaction dated Tuesday, November 14th. The stock was sold at an average price of $211.03, for a total value of $96,440.71. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Gail R. Wilensky sold 5,600 shares of the stock in a transaction dated Wednesday, November 29th. The stock was sold at an average price of $223.31, for a total value of $1,250,536.00. Following the completion of the sale, the director now owns 61,137 shares of the company’s stock, valued at $13,652,503.47. The disclosure for this sale can be found here. Insiders sold 33,655 shares of company stock valued at $7,469,083 over the last 90 days. Corporate insiders own 0.89% of the company’s stock.
Institutional investors have recently made changes to their positions in the business. Blue Chip Partners Inc. bought a new stake in shares of UnitedHealth Group in the second quarter worth about $110,000. Bruderman Asset Management LLC bought a new stake in shares of UnitedHealth Group in the second quarter worth about $114,000. Mitsubishi UFJ Securities Holdings Co. Ltd. increased its holdings in shares of UnitedHealth Group by 433.3% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 640 shares of the healthcare conglomerate’s stock worth $119,000 after acquiring an additional 520 shares in the last quarter. BDO Wealth Advisors LLC bought a new stake in shares of UnitedHealth Group in the second quarter worth about $121,000. Finally, Acrospire Investment Management LLC boosted its position in shares of UnitedHealth Group by 130.7% during the second quarter. Acrospire Investment Management LLC now owns 706 shares of the healthcare conglomerate’s stock worth $131,000 after buying an additional 400 shares during the period. Institutional investors own 86.09% of the company’s stock.
UnitedHealth Group Company Profile
UnitedHealth Group Incorporated is a health and well-being company. The Company operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight and OptumRx. It conducts its operations through two business platforms: health benefits operating under UnitedHealthcare and health services operating under Optum.
Receive News & Ratings for UnitedHealth Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group and related companies with MarketBeat.com's FREE daily email newsletter.